Cancer is a complex disease process that spans multiple scales in space and time. Driven by cutting-edge mathematical and computational techniques, in silico biology provides powerful tools to investigate the mechanistic relationships of genes, cells, and tissues. It enables the creation of experimentally testable hypotheses, the integration of dat

Mathematical modeling, analysis and simulation are set to play crucial roles in explaining tumor behavior, and the uncontrolled growth of cancer cells over multiple time and spatial scales. This book, the first to integrate state-of-the-art numerical techniques with experimental data, provides an in-depth assessment of tumor cell modeling at multiple scales. The first part of the text presents a detailed biological background with an examination of single-phase and multi-phase continuum tumor modeling, discrete cell modeling, and hybrid continuum-discrete modeling. In the final two chapters, the authors guide the reader through problem-based illustrations and case studies of brain and breast cancer, to demonstrate the future potential of modeling in cancer research. This book has wide interdisciplinary appeal and is a valuable resource for mathematical biologists, biomedical engineers and clinical cancer research communities wishing to understand this emerging field.

Mechanobiology: From Molecular Sensing to Disease will provide a review of the current state of understanding of mechanobiology and its role in health and disease. It covers: Current understanding of the main molecular pathways by which cells sense and respond to mechanical stimuli, A review of diseases that with known or purported mechanobiological underpinnings; The role of mechanobiology in tissue engineering and regenerative medicine; Experimental methods to capture mechanobiological phenomena; Computational models in mechanobiology. - Presents our current understanding of the main molecular pathways by which cells sense and respond to mechanical stimuli - Provides a review of diseases with known or purported mechanobiological underpinnings - Includes the role of mechanobiology in tissue engineering and regenerative medicine - Covers experimental methods to capture mechanobiological phenomena

Understanding how cancer tumours develop and spread is vital for finding treatments and cures. Cancer Modelling and Simulation demonstrates how mathematical modelling and computer simulation techniques are used to discover and gain insight into the dynamics of tumour development and growth. It highlights the benefits of tumour modelling, such as discovering optimal tumour therapy schedules, identifying the most promising candidates for further clinical investigation, and reducing the number of animal experiments. By examining the analytical, mathematical, and biological aspects of tumour growth and modelling, the book provides a common language and knowledge for professionals in several disciplines.

This work shows how the cellular Potts model can be used as a framework for model building and how extended models can achieve even better biological practicality, accuracy, and predictive power. It focuses on ways to integrate and interface the basic cellular Potts model at the mesoscopic scale with approaches that accurately model microscopic dynamics. These extensions are designed to create a nested and hybrid environment, where the evolution of a biological system is realistically driven by the constant interplay and flux of information between the different levels of description.

An overview of the current systems biology-based knowledge and the experimental approaches for deciphering the biological basis of cancer.

This volume – for pharmacologists, systems biologists, philosophers and historians of medicine – points to investigate new avenues in pharmacology research, by providing a full assessment of the premises underlying a radical shift in the pharmacology paradigm. The pharmaceutical industry is currently facing unparalleled challenges in developing innovative drugs. While drug-developing scientists in the 1990s mostly welcomed the transformation into a target-based approach, two decades of experience shows that this model is failing to boost both drug discovery and efficiency. Selected targets were often not druggable and with poor disease linkage, leading to either high toxicity or poor efficacy. Therefore, a profound rethinking of the current paradigm is needed. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggest that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets.